{"url":"https://lda.senate.gov/api/v1/filings/d42bf024-ce7d-438d-a26e-3b730df2acd7/","filing_uuid":"d42bf024-ce7d-438d-a26e-3b730df2acd7","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2018,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/d42bf024-ce7d-438d-a26e-3b730df2acd7/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jay B. Stewart","dt_posted":"2019-01-18T12:27:40.070000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"400 W. 15th Street, Suite 950","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"AUSTIN","registrant_state":"TX","registrant_zip":"78701","registrant":{"id":17443,"url":"https://lda.senate.gov/api/v1/registrants/17443/","house_registrant_id":30333,"name":"HANCE SCARBOROUGH","description":"Law Firm","address_1":"412 1st St SE","address_2":"Suite One","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAY B. STEWART","contact_telephone":"+1 512-479-8888","dt_updated":"2026-07-15T15:01:57.514279-04:00"},"client":{"id":123133,"url":"https://lda.senate.gov/api/v1/clients/123133/","client_id":1004342,"name":"TITAN PHARMACEUTICALS, INC.","general_description":"Specialty pharmaceuticals company","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-02-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":10001,"prefix":null,"prefix_display":null,"first_name":"KENT","nickname":null,"middle_name":"R","last_name":"HANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66821,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"TOMBERLIN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Chip Cravaack, Chief of Staff, Rep. Louie Gohmert","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":10001,"prefix":null,"prefix_display":null,"first_name":"KENT","nickname":null,"middle_name":"R","last_name":"HANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66821,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"TOMBERLIN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Chip Cravaack, Chief of Staff, Rep. Louie Gohmert","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":10001,"prefix":null,"prefix_display":null,"first_name":"KENT","nickname":null,"middle_name":"R","last_name":"HANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66821,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"TOMBERLIN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Chip Cravaack, Chief of Staff, Rep. Louie Gohmert","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":10001,"prefix":null,"prefix_display":null,"first_name":"KENT","nickname":null,"middle_name":"R","last_name":"HANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66821,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"TOMBERLIN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Chip Cravaack, Chief of Staff, REp. Louie Gohmert","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}